更昔洛韦治疗新生儿巨细胞病毒感染66例

Therapeutic effect of ganciclovir of 66 cases on neonatal human cytomegalovirus infections

目的:目的:观察更昔洛韦治疗新生儿巨细胞病毒(CMV)感染的疗效。方法:将新生儿巨细胞病毒感染的66例患儿随机分为两组,治疗组33例,应用更昔洛韦注射剂,诱导期7.5mg/(kg.次),每日2次,连续应用14d后改为10mg/(kg.d),每周3次,共维持3个月。对照组33例,应用利巴韦林注射剂,10mg/(kg.d),连用7d。两组均检测CMV-IgM判断疗效。结果:治疗组的转阴率为75.8%,对照组的转阴率为30.3%(P<0.01)。治疗过程中两组患儿均出现轻度肝功能受损及WBC,PLT减少,无显著差别(P>0.05)。结论:更昔洛韦治疗新生儿巨细胞病毒感染疗效较好,值得临床进一步推广。

Objective：To investigate the therapeutic effect of ganeielovir on neonatal human cytomegalovirus（CMV） infections. Methods：66 cases of neonatal CMV infections were divided into 2 groups,33 cases of treatment group was treated with grancicovir,7.5mg/kg at a time,intravenous drip every 12 hours, continuously using for 14 days. Then maintenance treatmentwith 10mg/kg intravenous drip everyday,for 3 -day everyweek,maintenance treatment for 3 months.Control group was treated with ribovivin 10mg/（kg·d） ,for 7 days. The serum CMV- IgM was measured.Results：Afterstreatment,the CMV- IgM negative rate（75.8%） in treatment groupwas higher than that in control group （30.3%）（ P 〈 0.01）.Conclusion：It is more effective with ganciclovir on neonatal human cytomegalovirus infections,and vas worth spreading.